Vol 4, No 4 (2003): Practical Diabetology
Research paper
Published online: 2003-09-18

open access

Page views 542
Article views/downloads 1525
Get Citation

Connect on Social Media

Connect on Social Media

Effects of treatment with HM insulin produced by Bioton, NovoNordisk and Eli Lilly in children with type 1 diabetes diagnosed in 2001 and 2002

Anna Noczyńska, Renata Wąsikowa
Diabetologia Praktyczna 2003;4(4):295-298.

Abstract

INTRODUCTION. The aim of the study was the appreciation of the degree of metabolic control in children treated with Bioton, Novo Nordisk or Eli Lilly insulin.
MATERIAL AND METHODS. Examined were 142 children with type 1 diabetes treated in the years 2001 and 2002, aged 2–18 years (mean 11,5 years). Analyzed were age, duration of the diabetes therapy, frequency of acute complications, HbA1c.
RESULTS. The mean levels of HbA1c were in the group 1 - 7,28%, group 2 - 6,58%, group 3 - 7,64%. In the investigated children severe hypoglycemia was not observed. Only in the group of 6 youngest children (< 5 years of age) in the course of acute infections observed were metabolic ketosis. In all the children observed was a decrease of insulin requirement but in none of them a complete remission.
CONCLUSION. The treatment with insulin Bioton, Novo Nordisk and Eli Lilly restored a good metabolic control in patients with type 1 diabetes. Patients treated with an intensive insulin therapy with a pen for an optimalisation of the metabolic control should receive an intermediate insulin at least in two daily doses.

Article available in PDF format

View PDF Download PDF file